Valuation of pipeline for fundraising activities

Challenge: An oncology biotech company with a proprietary therapeutics development platform technology was in the process of fundraising activities. The company's pipeline included three main...
Learn More

Valuation and deal making for oncology antibody

Challenge: A biotechnology company developing novel multi-specific antibody therapeutics to treat a range of cancers asked Alacrita to develop valuations for its four leading assets, as well as...
Learn More

Valuation of drug discovery company with Monte Carlo simulation

Challenge: A drug discovery company preparing for a forthcoming funding round wanted to update a valuation of the business based on a series of contract research projects and the proprietary value in...
Learn More

Dermatology due diligence and valuation

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.
Learn More

Valuation of a first in class, clinical stage small molecule to treat a range of tumor types

Challenge A private biotech company was preparing for an IPO. The company was developing a first-in-class small molecule inhibitor with the potential to treat a range of tumor types. The company was...
Learn More

Valuation and Partnering Support

Challenge A biotech company engaged in licensing discussions with a number of major pharma companies needed help with risk adjusted NPV (rNPV) valuations for each program.
Learn More

Monetizing oncology royalty streams

Challenge A licensor of a marketed oncology drug needed support with monetizing its royalty stream. Alacrita was engaged to develop an independent market-based valuation of the product.
Learn More

Helping an oncology company with a preclinical project to seek finance and potential acquisition

Challenge A virtual life science company had raised money from angel investors and anticipated a clinical development strategy for their product targeting two major cancer indications. The client...
Learn More

Valuing a cancer immunotherapy asset

Challenge A biotech company developing a cell-based cancer immunotherapy was engaged in licensing discussions with a number of major pharma companies and needed valuation support.
Learn More

Valuing multinational pharma company partnerships

Challenge A division of a multinational pharma company needed to evaluate a pipeline agreement with an antibody platform technology company. They wished to understand the overall value of the...
Learn More

Supporting a biotech company’s pharma partnerships

Challenge A biotech company needed support with an active partnering process with several major pharma companies.
Learn More

Evaluating a pipeline agreement with a platform technology company

Challenge A division of a multinational pharma company needed support evaluating a pipeline agreement with a platform technology company. The client wanted to know what the overall value of this...
Learn More